ELTP · XBRL financial data

Elite Pharmaceuticals financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ELTP's year ends in late March)

In millions of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Revenue	25	—	—	—	—	—
Revenue from contracts with customers	25	32	34	57	84	149
Cost of revenue	14	17	18	30	44	74
Gross profit	12	15	17	26	40	75
Research and development	5	4	6	7	8	6
General and administrative	3	4	5	7	9	18
Total operating expenses	10	10	13	16	20	26
Operating income (loss)	2	5	4	11	20	49
Interest income	0	0	0	0	0	0
Interest expense	0	0	1	1	0	0
Other income (expense)	2	—	—	—	—	—
Income tax expense (benefit)	—	(2)	0	(20)	4	12
Net income (loss)	5	9	4	20	(4)	45
Earnings per share, basic USD per share	0.01	0.01	0.00	0.02	0.00	0.04
Earnings per share, diluted USD per share	0.01	0.01	0.00	0.02	0.00	0.03
Weighted average shares, basic millions of shares	943	1,011	1,013	1,015	1,068	1,073
Weighted average shares, diluted millions of shares	943	1,011	1,013	1,023	1,068	1,138

Fiscal years (ELTP's year ends in late March)

In millions of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Cash and cash equivalents	3	9	8	7	12	30
Accounts receivable	3	3	3	19	29	60
Inventory	5	7	10	13	16	21
Prepaid and other current assets	0	1	1	1	1	1
Total current assets	12	19	22	40	58	112
Property and equipment, net	7	6	10	10	10	10
Right-of-use asset	0	1	0	2	2	2
Total assets	26	35	41	84	96	138
Accounts payable	1	1	2	3	3	6
Accrued liabilities	4	5	5	5	4	10
Total current liabilities	6	7	8	13	12	17
Lease liability, non-current	0	1	—	2	2	1
Total liabilities	10	10	12	26	43	39
Accumulated deficit	(149)	(140)	(136)	(116)	(121)	(76)
Total stockholders' equity	16	25	29	58	54	99
Total liabilities and equity	26	35	41	84	96	138
Common shares outstanding (cover page) millions of shares	1,009	1,011	1,014	1,068	1,068	1,077

Fiscal years (ELTP's year ends in late March)

In millions of dollars	FY 2021Mar 31, 2021	FY 2022Mar 31, 2022	FY 2023Mar 31, 2023	FY 2024Mar 31, 2024	FY 2025Mar 31, 2025	FY 2026Mar 31, 2026
Net income (loss)	5	9	4	20	(4)	45
Depreciation and amortization	1	1	1	1	1	1
Net cash from operating activities	3	7	3	(3)	7	24
Purchases of property and equipment	—	0	6	1	2	1
Net cash from investing activities	(0)	(0)	(6)	(1)	(2)	(1)
Proceeds from issuing common stock	0	—	—	—	—	—
Net cash from financing activities	(1)	(1)	2	3	(1)	(4)
Net change in cash	—	5	(1)	(1)	4	19

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Elite Pharmaceuticals	39	32	10	1.1B	—	Q1 FY27 10-QJun 30, 2026
Iovance Biotherapeutics	111	99	(61)*	453.0M	4.9 quarters	Q2 FY26 10-QJun 30, 2026
Opko Health	384	65	(36)*	742.5M	10.8 quarters	Q3 FY26 10-QSep 30, 2026
Savara	42	not reported	(30)*	205.5M	5.8 quarters	Q2 FY26 10-QJun 30, 2026
Xencor	60	117	2.6*	75.0M	—	Q3 FY26 10-QSep 30, 2026
Evolus	42	78	(1.9)*	66.2M	7.7 quarters	Q3 FY26 10-QSep 30, 2026
KalVista Pharmaceuticals	214	41	(14)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026
Kura Oncology	70	21	(63)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
Myriad Genetics	115	191	(8.3)*	95.6M	13.9 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.